share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股sec公告 ·  04/16 16:21
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc. officer Secora Michael is set to sell 25,000 Class A shares on 04/16/2024, as per the latest filing. The shares, valued at an aggregate market value of $191,658.73, were originally acquired on 04/20/2021 through a Pre IPO Option Exercise from the issuer. The acquisition was made with cash payment on the same date. This upcoming sale follows a series of transactions over the past three months where a total of 150,000 shares were sold, amounting to gross proceeds of $1,562,683.24. The notice of the planned sale was filed on the same date as the intended sale, with the plan for this transaction having been adopted on 03/01/2024.
Recursion Pharmaceuticals, Inc. officer Secora Michael is set to sell 25,000 Class A shares on 04/16/2024, as per the latest filing. The shares, valued at an aggregate market value of $191,658.73, were originally acquired on 04/20/2021 through a Pre IPO Option Exercise from the issuer. The acquisition was made with cash payment on the same date. This upcoming sale follows a series of transactions over the past three months where a total of 150,000 shares were sold, amounting to gross proceeds of $1,562,683.24. The notice of the planned sale was filed on the same date as the intended sale, with the plan for this transaction having been adopted on 03/01/2024.
根據最新文件,Recursion Pharmicals, Inc.高管塞科拉·邁克爾定於2024年4月16日出售25,000股A類股票。這些股票的總市值爲191,658.73美元,最初是在2021年4月20日通過發行人的首次公開募股前期權行使收購的。此次收購於同日以現金支付。此次即將進行的出售是在過去三個月進行的一系列交易之後進行的,共出售了15萬股股票,總收益爲1,562,683.24美元。計劃出售通知與預期銷售的同一天提交,該交易的計劃已於2024年1月3日通過。
根據最新文件,Recursion Pharmicals, Inc.高管塞科拉·邁克爾定於2024年4月16日出售25,000股A類股票。這些股票的總市值爲191,658.73美元,最初是在2021年4月20日通過發行人的首次公開募股前期權行使收購的。此次收購於同日以現金支付。此次即將進行的出售是在過去三個月進行的一系列交易之後進行的,共出售了15萬股股票,總收益爲1,562,683.24美元。計劃出售通知與預期銷售的同一天提交,該交易的計劃已於2024年1月3日通過。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息